Epigenetic Drugs for Soft Tissue Sarcomas
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Role of Xenobiotics".
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 2332
Special Issue Editor
Interests: cancer epigenetics; rhabdomyosarcoma; EZH2; SCLC; MYC; small molecules; nanoparticles; cytotoxicity; cell proliferation
Special Issue Information
Dear Colleagues,
Soft tissue sarcomas are a group of rare malignant tumors that develop from human soft tissues such as nerve, muscle, blood vessels, and fat. They originate from mesenchymal progenitor stem cells and are associated with a poor prognosis. The most common therapies include mainly surgical, chemotherapeutic, and radiotherapeutic approaches. However, the response rates of sarcomas to chemotherapy are rather low, and sarcoma cells may have intrinsic or acquired resistance after treatment with chemotherapeutic drugs, leading to the development of multidrug resistance (MDR). The overall 5-year survival rate of soft tissue sarcoma is 50%, and no particular improvements have been noted in the last few decades. Epigenetic dysregulation is very often observed in the pathogenesis of soft tissue sarcomas. More recently, epigenetic regulators, such as DNA methyltransferases, histone deacetylases, and histone-modifying enzyme Enhancer of Zeste Homolog 2 have gained attention as potential therapeutic targets. The recent development of numerous small-molecule inhibitors of these epigenetic regulators is allowing to identify novel potential therapeutic approaches in the treatment of different malignancies. However, epigenetic-targeted therapy in sarcomas still needs to be expanded and studied in order to understand the mechanisms to improve the clinical outcome. This Special Issue aims to gather reviews and original articles related to cutting-edge clinical advances in epigenetic therapies for soft tissue sarcomas, focusing also on treatments which combine epigenetic therapeutics to the current pharmacological therapies in order to improve clinical response.
Dr. Luigi M. Bagella
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- sarcomas
- epigenetics
- drugs
- rhabdomyosarcoma
- EZH2
- cytotoxicity
